(Q37590661)

21 August 2017

1 reference

title

Parkinson disease and comorbid cerebrovascular disease (English)

1 reference

21 August 2017

1 reference

6

Bastiaan R Bloem

1 reference

21 August 2017

author name string

Wandana Nanhoe-Mahabier

1

1 reference

21 August 2017

Karlijn F de Laat

2

1 reference

21 August 2017

Jasper E Visser

3

1 reference

21 August 2017

Jan Zijlmans

4

1 reference

21 August 2017

Frank-Erik de Leeuw

5

1 reference

21 August 2017

language of work or name

English

0 references

publication date

1 September 2009

1 reference

21 August 2017

published in

Nature Reviews Neurology

1 reference

21 August 2017

volume

5

1 reference

21 August 2017

issue

10

1 reference

21 August 2017

page(s)

533-541

1 reference

https://scigraph.springernature.com/pub.10.1038/nrneurol.2009.136

21 August 2017

exact match

0 references

cites work

Vascular risk factors, incidence of MCI, and rates of progression to dementia

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2009.136

Cigarette smoking and other risk factors for silent cerebral infarction in the general population.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2009.136

Blood pressure and plasma catecholamines in never-treated parkinsonian patients: effect of a selective D1 agonist (CY 208-243).

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2009.136

In vivo evidence that endogenous dopamine modulates sympathetic activity in man

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2009.136

Short-term predictors of incident stroke in older adults. The Cardiovascular Health Study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2009.136

Health benefits of physical activity: the evidence

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2009.136

Evidence for possible involvement of 5-HT(2B) receptors in the cardiac valvulopathy associated with fenfluramine and other serotonergic medications

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2009.136

Pergolide use in Parkinson disease is associated with cardiac valve regurgitation

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2009.136

Stroke and Parkinson's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2009.136

Parkinson's disease and its comorbid disorders: an analysis of Michigan mortality data, 1970 to 1990.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2009.136

MRI-defined vascular depression.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2009.136

'Vascular depression' hypothesis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2009.136

Cerebral white matter changes and geriatric syndromes: is there a link?

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2009.136

Idiopathic senile gait disorders are signs of subclinical disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2009.136

Cerebral white matter lesions and subjective cognitive dysfunction: The Rotterdam Scan Study

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2009.136

The Parkinson's complex: parkinsonism is just the tip of the iceberg

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2009.136

The pre-therapeutic classification of co-morbidity in chronic disease

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2009.136

Nordic walking improves mobility in Parkinson's disease

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2009.136

Exercise and carotid atherosclerosis

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2009.136

Cigarette smoking in Parkinson's disease: influence on disease progression

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2009.136

Clinicopathological investigation of vascular parkinsonism, including clinical criteria for diagnosis

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2009.136

Diagnostic criteria for Parkinson disease

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2009.136

Stroke and its modification in Parkinson's disease

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2009.136

Smoking and Parkinson's disease

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2009.136

Parkinson's disease, stroke, and related epidemiology.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2009.136

Progression of cerebral small vessel disease in relation to risk factors and cognitive consequences: Rotterdam Scan study

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2009.136

Incidence, manifestations, and predictors of worsening white matter on serial cranial magnetic resonance imaging in the elderly: the Cardiovascular Health Study

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2009.136

Cigarette smoking as a risk factor for stroke. The Framingham Study

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2009.136

Cigarette Smoking and Progression of Atherosclerosis

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2009.136

The effects of tobacco smoke and nicotine on cognition and the brain

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2009.136

Sympathetic modulation by levodopa reduces vascular risk factors in Parkinson disease

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2009.136

Catecholamines: role in health and disease

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2009.136

Impaired cardiovascular autonomic control in newly and long-term-treated patients with Parkinson's disease: involvement of L-dopa therapy

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2009.136

Hypotensive effect of long-term levodopa in patients with Parkinson's disease

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2009.136

Effect of L-dopa in young patients with hypertension

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2009.136

Autonomic nervous system dysfunction in Parkinson's disease: relationships with age, medication, duration, and severity

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2009.136

Management of neurogenic orthostatic hypotension: an update

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2009.136

Sympathetically mediated hypertension in autonomic failure

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2009.136

Association between supine hypertension and orthostatic hypotension in autonomic failure

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2009.136

Drug-Induced Orthostatic Hypotension

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2009.136

Orthostatic hypotension in patients with Parkinson's disease: pathophysiology and management.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2009.136

Drug-induced orthostatic hypotension in the elderly: avoiding its onset

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2009.136

Alternatives to levodopa in the initial treatment of early Parkinson's disease

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2009.136

Hypertension and cerebral white matter lesions in a prospective cohort study.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2009.136

Orthostatic hypotension as a risk factor for stroke: the atherosclerosis risk in communities (ARIC) study, 1987-1996

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2009.136

Physical activity intervention studies: what we know and what we need to know: a scientific statement from the American Heart Association Council on Nutrition, Physical Activity, and Metabolism (Subcommittee on Physical Activity); Council on Cardiov

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2009.136

Physical activity and sports in patients suffering from Parkinson's disease in comparison with healthy seniors.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2009.136

Free-living daily energy expenditure in patients with Parkinson's disease.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2009.136

Physical activity and stroke. A meta-analysis of observational data

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2009.136

Association of leisure time physical activity with the risk of coronary heart disease, hypertension and diabetes in middle-aged men and women.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2009.136

Assessment of valvulopathy in Parkinson's disease patients on pergolide and/or cabergoline

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2009.136

Valvular heart disease in Parkinson's disease treated with ergot derivative dopamine agonists

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2009.136

Cardiac valve regurgitation with pergolide compared with nonergot agonists in Parkinson disease

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2009.136

Treatment of Parkinson's disease with pergolide and relation to restrictive valvular heart disease

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2009.136

Dopamine agonists and the risk of cardiac-valve regurgitation

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2009.136

Valvular heart disease and the use of dopamine agonists for Parkinson's disease

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2009.136

Fibrotic heart-valve reactions to dopamine-agonist treatment in Parkinson's disease

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2009.136

Valvular heart disease as a cause of cerebrovascular disease in patients with systemic lupus erythematosus.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2009.136

Elevated plasma levels of homocysteine in Parkinson's disease

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2009.136

Hyperhomocysteinaemia in Parkinson's disease

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2009.136

Effects of levodopa and COMT inhibitors on plasma homocysteine in Parkinson's disease patients

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2009.136

Hyperhomocysteinemia in L-dopa treated Parkinson's disease patients: effect of cobalamin and folate administration

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2009.136

Nigral endothelial dysfunction, homocysteine, and Parkinson's disease

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2009.136

The clinical potential of ademetionine (S-adenosylmethionine) in neurological disorders

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2009.136

Physiological increments in plasma homocysteine induce vascular endothelial dysfunction in normal human subjects

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2009.136

Homocysteine, silent brain infarcts, and white matter lesions: The Rotterdam Scan Study

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2009.136

Mortality and cardiovascular events in patients treated with homocysteine-lowering B vitamins after coronary angiography: a randomized controlled trial

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2009.136

Homocysteine lowering and cardiovascular events after acute myocardial infarction

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2009.136

Lowering homocysteine in patients with ischemic stroke to prevent recurrent stroke, myocardial infarction, and death: the Vitamin Intervention for Stroke Prevention (VISP) randomized controlled trial

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2009.136

Accuracy of clinical diagnosis of idiopathic Parkinson's disease: a clinico-pathological study of 100 cases

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2009.136

Visual rating of white matter hyperintensities in Parkinson's disease.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2009.136

Prevalence of stroke in Parkinson's disease: a postmortem study.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2009.136

White matter hyperintensities in Parkinson's disease. Clinical correlations

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2009.136

White matter involvement in idiopathic Parkinson disease: a diffusion tensor imaging study.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2009.136

Survival and cause of death in a cohort of patients with parkinsonism: possible clues to aetiology?

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2009.136

Vascular pathology in patients with idiopathic Parkinson's disease

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2009.136

Clinical course of patients with idiopathic Parkinson's disease.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2009.136

Assessing comorbidity in patients with Parkinson's disease

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2009.136

Basal ganglia lacunes and parkinsonism.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2009.136

The effect of vascular disease on late onset Parkinson's disease

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2009.136

Frequency of dementia in Parkinson disease.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2009.136

Intentionally staged operation for large and high-flow cerebral arteriovenous malformation.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2009.136

A regions-of-interest volumetric analysis of mobility limitations in community-dwelling older adults

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2009.136

Association of gait and balance disorders with age-related white matter changes: The LADIS Study

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2009.136

A meta-analysis of six prospective studies of falling in Parkinson's disease

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2009.136

[Dysequilibrium in idiopathic Parkinson disease. The effect of cerebrovascular comorbidity]

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2009.136

Potential surrogate markers of cerebral microvascular angiopathy in asymptomatic subjects at risk of stroke

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2009.136

Cerebral White Matter Lesions and Depressive Symptoms in Elderly Adults

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2009.136

A study on symptom profiles of late-life depression: the influence of vascular, degenerative and inflammatory risk-indicators.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2009.136

Biological risk factors for late life depression

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2009.136

The influence of cerebrovascular risk factors on incident dementia in patients with Parkinson's disease.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2009.136

Homocysteine and cognitive impairment in Parkinson's disease: a biochemical, neuroimaging, and genetic study.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2009.136

Periventricular cerebral white matter lesions predict rate of cognitive decline

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2009.136

Self-perceived memory impairment and cognitive performance in an elderly independent population with age-related white matter changes.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2009.136

Cerebral white matter lesions and the risk of dementia.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2009.136

Neuroimaging correlates of subjective memory deficits in a community population.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2009.136

White matter lesions are associated with progression of medial temporal lobe atrophy in Alzheimer disease.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2009.136

The relationship between Parkinson's disease and dementia. A study using proton NMR imaging parameters.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2009.136

Impact of white matter changes on clinical manifestation of Alzheimer's disease: A quantitative study

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2009.136

Urinary function in elderly people with and without leukoaraiosis: relation to cognitive and gait function

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2009.136

Clinical features of leuko-araiosis.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2009.136

Clinical correlates of high signal lesions on magnetic resonance imaging in Alzheimer's disease

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2009.136

Functional anatomy of the organs of micturition

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2009.136

A PET study on brain control of micturition in humans

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2009.136

The central nervous system control of micturition in cats and humans.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2009.136

Bladder dysfunction in Parkinsonism: mechanisms, prevalence, symptoms, and management.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2009.136

Prevalence of bladder dysfunction in Parkinsons disease.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2009.136

Falls in outpatients with Parkinson's disease: frequency, impact and identifying factors

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2009.136

Guidelines for prevention of stroke in patients with ischemic stroke or transient ischemic attack: a statement for healthcare professionals from the American Heart Association/American Stroke Association Council on Stroke...

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2009.136

Update to the AHA/ASA recommendations for the prevention of stroke in patients with stroke and transient ischemic attack

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2009.136

New insight into Binswanger disease.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2009.136

Falls, faints, fits and funny turns

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2009.136

Is physical exercise beneficial for persons with Parkinson's disease?

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2009.136

The effects of physical therapy in Parkinson's disease: a research synthesis

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2009.136

Evidence-based analysis of physical therapy in Parkinson's disease with recommendations for practice and research

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2009.136

Betel quid: Its tremor-producing effects in residents of Araihazar, Bangladesh.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2009.136

Valvular heart disease in patients with Parkinson's disease treated with pergolide. Course following treatment modifications

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2009.136

Overview of morphological changes in Parkinson's disease

31 March 2020

1 reference

12 December 2020

Prevalence of cerebrovascular lesions in Parkinson's disease. A postmortem study

1 reference

12 December 2020

Urinary dysfunction in Parkinson's disease

1 reference

12 December 2020

[Quality and life style as risk factors in acute cerebrovascular disease]

1 reference

12 December 2020

The influence of vascular risk factors and white matter hyperintensities on the degree of cognitive impairment in Parkinson's disease.

1 reference

12 December 2020

Effect of exercise on perceived quality of life of individuals with Parkinson's disease.

1 reference

12 December 2020

10.1038/NRNEUROL.2009.136

Identifiers

DOI

1 reference

21 August 2017

1 reference